Hemeoxygenase-1 mediated hypercoagulability in a patient with thyroid cancer

Vance G. Nielsen, Benjamin D. Garol, Eric A. Zelman, Marlon A. Guerrero

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Thyroid cancers can cause significant regional thrombotic morbidity and mortality. Of interest, thyroid cancer cell lines can have upregulation of the carbon monoxide-producing enzyme, hemeoxygenase-1. Carbon monoxide has been demonstrated to markedly enhance plasmatic coagulation in vitro and in vivo via enhancement of fibrinogen's substrate properties by binding to a fibrinogen-associated heme group(s). We present a patient undergoing removal of a malignant thyroid tumour who was serendipitously found to have abnormally increased carboxyhaemoglobin concentration (2.4%) and plasmatic hypercoagulability with a carbon monoxide-mediated clot strength as determined by a thrombelastographic method. This initial observation serves as a rationale to further investigate the role played by hemeoxygenase-1 upregulation in the setting of cancers associated with increased endogenous carbon monoxide production.

Original languageEnglish (US)
Pages (from-to)663-665
Number of pages3
JournalBlood Coagulation and Fibrinolysis
Issue number6
StatePublished - Sep 2013


  • carbon monoxide
  • hemeoxygenase-1
  • thrombelastography
  • thrombosis
  • thyroid cancer

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Hemeoxygenase-1 mediated hypercoagulability in a patient with thyroid cancer'. Together they form a unique fingerprint.

Cite this